We are live on
!
Find out more
CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
30 hedge funds and large institutions have $12.1M invested in Cymabay Therapeutics in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 29 → 30 (+1)
33% less capital invested
Capital invested by funds: $18.1M → $12.1M (-$6.04M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.8%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
4
Increased
3
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62.7K |
| 2 |
Renaissance Technologies
New York
|
+$62.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.09K |
| 5 |
Barclays
London,
United Kingdom
|
+$1.61K |
